Immune Design deprioritizes synovial sarcoma compound CMB305

Immune Design Corp. (NASDAQ:IMDZ) discontinued the Phase III SYNOVATE trial of CMB305 monotherapy to treat synovial sarcoma after an early analysis of a Phase II trial in the indication showed that CMB305 in combination with anti-PD-L1 mAb Tecentriq atezolizumab was unlikely to show a survival benefit. The company will seek to partner CMB305 to explore further development of the compound in sarcoma.

Immune Design said it will now focus on development of G100, a toll-like receptor 4 (TLR4) agonist in Phase I/II testing to treat follicular non-Hodgkin lymphoma (NHL). The company said the portfolio prioritization will extend its cash runway into 2021. In an Aug. 1 SEC filing, Immune Design said it would have runway through at least August 2019. At June 30, it had $120.2 million in cash and a six-month operating loss of $28.2 million...